TScan Therapeutics
TCRX
28 hedge funds and large institutions have $20.3M invested in TScan Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
37% more capital invested
Capital invested by funds: $14.8M → $20.3M (+$5.52M)
0.78% more ownership
Funds ownership: 50.26% → 51.04% (+0.78%)
0% more funds holding
Funds holding: 28 → 28 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$1.3M |
| 2 |
Morgan Stanley
New York
|
+$212K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$73.1K |
| 4 |
State Street
Boston,
Massachusetts
|
+$25.2K |
| 5 |
WPW
Waldron Private Wealth
Bridgeville,
Pennsylvania
|
+$23.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$798K |
| 2 |
Millennium Management
New York
|
-$31K |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$20.9K |
| 4 |
LPL Financial
San Diego,
California
|
-$11.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $420 | -$81 | -34 | -15% |
|
27
Wells Fargo
San Francisco,
California
| $158 | +$5 | +2 | +3% |
|
28
Osaic Holdings
Scottsdale,
Arizona
| $2 | +$2 | +1 | New |
|
|
TCM
29
Tang Capital Management
San Diego,
California
| – | -$798K | -514,655 | Closed |
|
|
30
Millennium Management
New York
| – | -$31K | -19,244 | Closed |
|
|
31
Prudential Financial
Newark,
New Jersey
| – | -$20.9K | -12,800 | Closed |
|
TCRX Hedge Fund Activity: Q1 2023 in Review
28 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q1 2023, worth a combined $20.3M — up 37% from $14.8M a quarter earlier.
Fund positioning in TCRX was balanced in Q1 2023: 3 funds opened new positions, 3 closed out, 9 added to existing stakes and 3 trimmed.
The largest buyer was Simplify Asset Management, opening a new position worth an estimated $1.3M. The largest seller was Tang Capital Management, exiting entirely with an estimated $798K sold.
- 28 institutional investors held TScan Therapeutics (TCRX) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $20.3M of TScan Therapeutics stock for Q1 2023, up 37% quarter-over-quarter.
- 3 funds opened new TScan Therapeutics positions in Q1 2023 and 3 closed out, a net change of 0 holders.
- The largest TScan Therapeutics buyer in Q1 2023 was Simplify Asset Management, an estimated $1.3M added.
- The largest TScan Therapeutics seller in Q1 2023 was Tang Capital Management, an estimated $798K sold.
Based on aggregated 13F filings for Q1 2023.